This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alexe, G. Articles by Bhanot, G. Search for Related Content PubMed PubMed Citation Articles by Alexe, G. Articles by Bhanot, G.

High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates

¹ The Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts; ² The Simons Center for Systems Biology, Institute for Advanced Study, Princeton, New Jersey; ³ Molecular Biology, Cellular Biology and Biochemistry Program, ⁴ Department of Biomedical Engineering, Boston University, Boston, Massachusetts; ⁵ Yale Cancer Center and ⁶ Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; ⁷ Robert Wood Johnson University Hospital, and ⁸ Cancer Institute of New Jersey, New Brunswick, New Jersey; and ⁹ BioMaPS Institute and Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey

Requests for reprints: Gyan Bhanot, BioMaPs Institute, Rutgers University, 271 Hill Center, Piscataway, NJ 08854. Phone: 732-235-9545; E-mail: gyanbhanot{at}gmail.com and Shridar Ganesan, Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903. Phone: 732-235-5211; E-mail: ganesash{at}umdnj.edu.

Gene expression analysis has identified biologically relevant subclasses of breast cancer. However, most classification schemes do not robustly cluster all HER2+ breast cancers, in part due to limitations and bias of clustering techniques used. In this article, we propose an alternative approach that first separates the HER2+ tumors using a gene amplification signal for Her2/neu amplicon genes and then applies consensus ensemble clustering separately to the HER2+ and HER2– clusters to look for further substructure. We applied this procedure to a microarray data set of 286 early-stage breast cancers treated only with surgery and radiation and identified two basal and four luminal subtypes in the HER2– tumors, as well as two novel and robust HER2+ subtypes. HER2+ subtypes had median distant metastasis-free survival of 99 months [95% confidence interval (95% CI), 83–118 months] and 33 months (95% CI, 11–54 months), respectively, and recurrence rates of 11% and 58%, respectively. The low recurrence subtype had a strong relative overexpression of lymphocyte-associated genes and was also associated with a prominent lymphocytic infiltration on histologic analysis. These data suggest that early-stage HER2+ cancers associated with lymphocytic infiltration are a biologically distinct subtype with an improved natural history. [Cancer Res 2007;67(22):10669–76]

This article has been cited by other articles:

				M. Schmidt, J. G. Hengstler, C. von Torne, H. Koelbl, and M. C. Gehrmann Coordinates in the Universe of Node-Negative Breast Cancer Revisited Cancer Res., April 1, 2009; 69(7): 2695 - 2698. [Abstract] [Full Text] [PDF]

				M. Schmidt, D. Bohm, C. von Torne, E. Steiner, A. Puhl, H. Pilch, H.-A. Lehr, J. G. Hengstler, H. Kolbl, and M. Gehrmann The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer Cancer Res., July 1, 2008; 68(13): 5405 - 5413. [Abstract] [Full Text] [PDF]